Neogen Corporation (NASDAQ:NEOG) Q1 2023 Earnings Conference Call September 27, 2022 11:00 AM ET Company Participants John Adent - President and CEO Steve Quinlan - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Brandon Vazquez - William Blair Operator Good day and welcome to the Neogen Corporation First Quarter Fiscal Year 2023 Earnings Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to John Adent, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended May 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To . COMMISSION FILE NUMBER 0-17988 NEOGEN CORPORATION (Exact name of registrant as specified in its charter) MICHIGAN 38-2367843 (State of other jurisdiction of ...

Neogen Corporation (NASDAQ:NEOG) Q4 2022 Earnings Conference Call July 26, 2022 11:00 AM ET Company Participants John Adent - President and CEO Steve Quinlan - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good morning. And welcome to the Neogen Corporation Fourth Quarter and Full Year 2022 Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today???s presentation, there will be an opportunity to ask questions. [Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 v FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17988 Neogen Corporation 620 Lesher Place Lansing, Michigan 48912 (Address of principal executive offices ...

Neogen Corporation. (NASDAQ:NEOG) Q3 2021 Earnings Conference Call March 24, 2022 11:00 AM ET Company Participants John Adent - President and Chief Executive Officer Steve Quinlan - Chief Financial Officer Conference Call Participants Christine Rains - William Blair David Westenberg - Piper Sandler Operator Good day and welcome to the Neogen Corporation Third Quarter Fiscal Year 2022 Earnings Conference Call. [Operator Instructions]. Please note, this event is being recorded. I would now like to turn the co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17988 Neogen Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 13% year-over-year, with sales reaching $130.5 million for the second quarter [5][13] - Operating income, excluding $9.3 million in costs related to the 3M deal, was $21.8 million, representing a 13% increase compared to the prior year [30] - Gross margins improved slightly to 46.4% from 46.3% in the previous year, despite rising costs [25] Business Line Data and Key Metrics Changes - Food Safety segment revenues increased by 17% to $67.1 million, with organic growth of 11% [13] - Animal Safety segment revenues rose by 10% to $63.4 million, with notable growth in veterinary instruments (30%) and insect control products (46%) [19][20] - Sales of dairy drug residue test kits declined by 23% due to competitive pressures and the end of a distribution agreement [18] Market Data and Key Metrics Changes - U.S. revenues increased over 9%, while international operations saw a 20% rise, with notable growth in China (28%) and the U.K. (20%) [22][23] - The company experienced a 14% increase in international sales when excluding the Megazyme acquisition [22] Company Strategy and Development Direction - The company announced a significant merger with 3M's Food Safety business, aiming to enhance its product offerings and geographic footprint [6][8] - Recent acquisitions, including CAPInnoVet and Genetic Veterinary Services, are part of the strategy to diversify and strengthen the Animal Safety segment [10][40] - The focus remains on expanding companion animal offerings while integrating the 3M business [40] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing recovery from the COVID-19 pandemic and the strong performance in the current quarter [35] - The company is actively addressing supply chain challenges and labor shortages while maintaining gross margins [14][25] - Future growth is anticipated from the integration of 3M's business and the continued development of new products [41] Other Important Information - The company incurred $9.3 million in professional fees related to the 3M merger, impacting general and administrative costs [27] - Inventory levels increased by $6.4 million, attributed to recent acquisitions and supply chain issues [32] Q&A Session Summary Question: Differences in 3M's product lineup and integration plans - Management highlighted the complementary nature of 3M's products, particularly in pathogen testing, and outlined a structured integration plan [45][47] Question: Concerns about international operations being cash flow negative - Management indicated that while initial investments in new markets may be dilutive, established international markets are profitable and will benefit from the merger [52][53] Question: Assurance on expanding into companion animal market while integrating 3M - Management reassured that the leadership team is strong and capable of managing both the integration and growth in the companion animal segment [55][56] Question: Trends in customer consolidation and pricing implications - Management noted that while consolidation among food producers continues, the company’s broad product offerings provide competitive advantages in pricing [60][62]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2021. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17988 Neogen Corporation (Exact name of registrant as specified in its charter) Michigan 38-2367843 (State or ...

Neogen Corporation (NASDAQ:NEOG) Q1 2022 Earnings Conference Call September 21, 2021 11:00 AM ET Company Participants John Adent - Chief Executive Officer and President Steve Quinlan - Chief Financial Officer Conference Call Participants David Westenberg - Guggenheim Securities John Kreger - William Blair Operator Good day, and welcome to the Neogen First Quarter Fiscal Year 2022 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over ...

Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended May 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To . COMMISSION FILE NUMBER 0-17988 NEOGEN CORPORATION (Exact name of registrant as specified in its charter) MICHIGAN 38-2367843 (State of oth ...